Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria

  1. J. A. Paniagua1,
  2. J. López-Miranda1,
  3. P. Pérez-Martínez1,
  4. C. Marín1,
  5. J. M. Vida2,
  6. F. Fuentes1,
  7. R. A. Fernández de la Puebla1,
  8. F. Pérez-Jiménez1,*

Article first published online: 29 JUN 2005

DOI: 10.1111/j.1464-5491.2005.01703.x

Issue

Diabetic Medicine

Diabetic Medicine

Volume 22, Issue 12, pages 1647–1656, December 2005

Additional Information

How to Cite

Paniagua, J. A., López-Miranda, J., Pérez-Martínez, P., Marín, C., Vida, J. M., Fuentes, F., Fernández de la Puebla, R. A. and Pérez-Jiménez, F. (2005), Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria. Diabetic Medicine, 22: 1647–1656. doi: 10.1111/j.1464-5491.2005.01703.x

Author Information

  1. 1

    Lipid and Atherosclerosis Unit and

  2. 2

    Department of Vascular Radiology, University Hospital Reina Sofia, Córdoba, Spain

*F. Pérez Jiménez, Unidad de Lípidos y Arteriosclerosis, Hospital Universitario Reina Sofía, Avda Menéndez Pidal, s/n. 14004, Córdoba. Spain. E-mail: md1pejif@uco.es; jpaniaguag@supercable.es

Publication History

  1. Issue published online: 29 JUN 2005
  2. Article first published online: 29 JUN 2005
  3. Accepted 11 February 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (236K)

Keywords:

  • endothelium;
  • microalbuminuria;
  • oxidative stress;
  • statin;
  • Type 2 diabetes

Abstract

Aims  To investigate the role of HMG-CoA reductase inhibitor (statin) treatment during serum glucose variations on plasma oxidized LDL (ox-LDL) levels in obese patients with early Type 2 diabetes mellitus (T2D) and its relationship to endothelial biomarkers.

Methods  In a double-blind, randomized crossover study, 15 obese diet-treated T2D patients received cerivastatin (0.4 mg/day) or placebo for 3 months. Circulating ox-LDL levels were measured fasting and during a euglycaemic–hyperinsulinaemic clamp (∼5.5 mmol/l; EHC) and a hyperglycemic clamp (∼20 mmol/l; HC). An endothelium-dependent flow-mediated dilation (FMD) study was carried out and urinary albumin excretion (UAE) was measured at rest and during EHC. S-ICAM, s-VCAM and basal prothrombotic factors were also measured.

Results  During cerivastatin treatment, basal circulating ox-LDL levels decreased by 48% (P < 0.001) compared with placebo. Serum ox-LDL levels decreased during EHC and remained unchanged during HC compared with the fasting state; with cerivastatin treatment these levels were lower compared with placebo both in the fasting state and during the clamp studies. FMD was higher with cerivastatin than with placebo (P < 0.001) and the increments in FMD correlated with decrements in serum ox-LDL levels (r = 0.78, P = 0.001). Microalbuminuria increased during EHC but this was blunted during cerivastatin therapy compared with placebo (P < 0.05). Basal sICAM-1 and sVCAM-1 levels decreased (P < 0.01 and P < 0.05, respectively).

Conclusions  In early obese Type 2 diabetic patients, serum ox-LDL levels are influenced by short-term serum glucose variations and lowered with cerivastatin therapy. During cerivastatin treatment, improved flow-mediated endothelium-dependent dilation was associated with decrements in circulating ox-LDL levels and the hyperinsulinaemia-induced urinary albumin excretion was blunted.

View Full Article (HTML) Get PDF (236K)